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S286 Poster Session IIBackground: Approximately a third of all Allogeneic stem cell
transplants performed now use unrelated donors. Usually donors
have stem cells collected at centres distant from the transplant
centre. NMDP data indicates that the length of travel time and
the wait time before infusion does not affect neutrophil engraft-
ment time. A higher overall mortality was associated with bone
marrow grafts which had a combined travel and wait time
of$ 26 hours.
Method: A retrospective chart review was undertaken at Wel-
lington Hospital looking at consecutive MUD transplants be-
tween March 2004 and June 2009. Data were collected on the
disease, donor location, stem cell source, travel times, wait
time at the transplant centre before infusion, neutrophil and
platelet engraftment; and early (prior to Day +100) and overall
mortality.
Result: There were 26 consecutive MUD transplants performed
during the study period. A single cord blood transplant was ex-
cluded from analysis. 52% donor stem cells had travel times to
the transplant centre of$ 20 hours. The time between the arrival
of stem cells at the transplant centre to infusion into the patient
ranged from 1 – 42 hours. Extended travel and wait times did not
appear to impact on neutrophil or platelet recovery (median time
to neutrophil engraftment5 16 days, platelet engraftment5 20
days) or mortality.
Conclusion: The majority of collections for our centre were from
Germany. In all cases, combined travel and wait times before infu-
sions were greater than 30 hours. With the caveat of small numbers,
there appeared to be no difference in neutrophil and platelet engraft-
ment times or to early or overall mortality. In some cases there were
considerable delays between stem cells arriving at the transplant cen-
tre and infusion into the patient. Our remote location and the logis-
tics related to flight arrival times and TBI timing make this
unavoidable.345
LOW-DOSE ANTI-T-LYMPHOCYTE GLOBULIN (ATG-FRESIUS) SIGNIFI-
CANTLY REDUCES ACUTE GVHD AND NON-RELAPSE MORTALITY
(NRM) AFTER REDUCED-INTENSITY UNRELATED BMT
Ueno, N., Fuji, S., Fukuda, T., Yakushijin, K., Kurosawa, S.,
Asakura, Y., Mori, M., Hiramoto, N., Kamiyama, Y., Fukuhara, S.,
Kim, S.-W., Mori, S., Tanosaki, R., Heike, Y., Takaue, Y. National Can-
cer Center Hospital, Tokyo, Japan
Introduction: Unrelated HSCT with a reduced-intensity condi-
tioning regimen (RIC) is now widely performed as an alternative
to HLA-matched related HSCT. However, the optimal regimen
has not yet been well established in Japan, where peripheral blood
stem cell transplantation is not yet allowed for unrelated pairs. In
this retrospective analysis of unrelated RIC BMT, we evaluated
the feasibility of a regimen using a lower dose of rabbit ATG (Fre-
sius) and TBI.
Patients and Methods: From January 2000 to May 2009, 108
patients received unrelated BMT with a RIC regimen that in-
cluded fludarabine or cladribine plus busulfan. Additionally, 30
patients received 4 Gy TBI, 45 received 2 Gy TBI, and 33 re-
ceived lower doses of ATG (5 mg/kg, n5 20; 10 mg/kg,
n5 13). Endpoints included the probability of acute GVHD,
engraftment, NRM, overall survival (OS) and progression-free
survival (PFS).
Results: The probability of grade II-IV acute GVHD was, respec-
tively, 58%, 71%, and 17% in the 4 Gy TBI, 2 Gy TBI and ATG-
containing groups (P5 0.0002). The probability of grade III-IV
acute GVHD was, respectively, 37%, 9% and 0% in the 4 Gy
TBI, 2 Gy TBI and ATG-containing groups (P5 0.0002). There
were 7 graft failures in the ATG group (1 primary and 6 second-
ary), 1 secondary graft failure was observed in the 4 Gy group
and 1 primary graft failure was seen in the 2 Gy group. The prob-
ability of NRM at 1 year was 48% in the 4 Gy group, 17% in the
2 Gy group and 0% in the ATG group. At 2 years, this was 52% in
the 4 Gy group, 23% in the 2 Gy group and 19% in the ATG
group (P5 0.003). The probability of death due to relapse/pro-
gression at 2 years was 19% in the 4 Gy group, 36% in the 2 Gygroup and 32% in the ATG group (P5 0.32). The 2-year OS
was 40% in the 4 Gy group, 50% in the 2 Gy group and 60% in
the ATG group (P5 0.05). The 2-year PFS was 40% in the
4 Gy group, 50% in the 2 Gy group and 52% in the ATG group
(P5 0.21).
Conclusion: A lower dose of ATG-Fresius (5-10 mg/kg) signifi-
cantly reduced the risk of acute GVHD and NRM compared to
low-dose TBI after unrelated BMT in a RIC setting, despite an as-
sociated higher rate of secondary graft failure. These findings will
need to be confirmed in a larger prospective randomized-
controlled trial.346
PROGNOSTIC INDEXES IS NOT PREDICTIVE OF TREATMENT RELATED
MORTALITY IN PATIENTS (PTS) OLDER THAN 60 YEARS TREATED
WITH REDUCED INTENSITY CONDITIONING AND ALLOGENEIC STEM
CELL TRANSPLANTATION (RIC-ALLO)
Castagna, L.1, Marchetti, N.2, Fu¨rst, S.1, El-Cheikh, J.1, Faucher, C.1,
Vey, N.1, Bouabdallah, R.1, Stoppa, A.-M.1, Mohty, M.3, Esterni, B.4,
Blaise, D.1 1 Institut Paoli Calmettes, Marseille, France; 2Hopital Maciel,
Montevideo, Uruguay; 3Hotel Dieu, Nantes, France; 4 Institut Paoli
Calmettes, Marseille, France
Background: For many maligant diseases, median age at diagno-
sis is around the sixth decade of life, precluding myeloablative
ALLO. RIC-ALLO is less toxic and has been performed in el-
derly pts, mainly affected by acute leukemia. Prognostic indexes
seem to predict treatment related mortality (TRM) and overall
survival (OS).
Patients and methods: From 2001 and 2008, 63 pts older than 60
years (median age 63 y, range 60-70) received RIC-ALLO. Dis-
eases were: acute myeloid leukemia 45%, and chronic lymphopro-
liferative diseases 54%. Disease status at RIC-ALLO was: complete
remission 54%, partial remission 16%, and active disease 30%.
RIC consisted of fludarabine-based with thymoglobulin 64%, or
low-dose TBI-based 36%. Donors were: HLAid sibling 73%,
matched unrelated 21%, and cord blood 6%. Three prognostic
scores were evaluated.
Results: The median follow-up was 22 months. The 2-y OS and
PFS were 66.8% (IC95; 55.5-80.4) and 52.4% (IC95:39.5-69.5), re-
spectively. Grade II-IV acute graft versus host disease (aGVHD) and
chronic GVHD (cGVHD) incidence were 49% and 43%, respec-
tively. Early infections were fever of unknown origin in 42% of
pts, bacterial infection in 6 cases, pneumonia in 8, and viral infections
in 14. The early infection-related mortality was null. Late infections
were bacterial in 3 cases, pneumonia in 1, viral infections in 6, and
candidemia in 1. Seven pts died from late infective complications.
Overall, the cause of death was toxicities in 18 pts and disease pro-
gression in 6 pts. The 100-d and 1-y TRM were 6% and 24%, re-
spectively.
In univariate analysis, HCT-CI, EBMT score, and PAM score did
not influence TRM or OS. Furthermore, age (60-65 vs 66-70) was
not related to TRM. Only severe aGVHD was predictive.
Conclusions: The aim of this retrospective study was to assess
if TRM was excessively high in elderly pts, after ALLO-RIC.
A secondary objective was to evaluate if any of the current
prognostic indexes could predict TRM and OS in this peculiar
population. TRM was acceptable and not different when com-
pared to younger pts as reported in literature. Furthermore,
neithe prognostic index nor age help segregating a group of
pts with higher TRM limiting their value for treatment decision
in this situation.347
ABSOLUTE NEUTROPHIL COUNT LESS THAN 0.2  109/L ON DAY SIX-
TEEN POST-TRANSPLANT MARKEDLY INCREASES THE RISK OF GRAFT
FAILURE
Olsson, R., Remberger, M., Ringden, O. Karolinska University Hospital,
Stockholm, Sweden
Following allogeneic hematopoietic stem cell transplantation
(HSCT) graft failure is a major complication, which markedly
Poster Session II S287decreases overall survival. Several risk factors for graft failure have
been reported, such as reduced intensity conditioning, HLA-mis-
match, T-cell depleted grafts etc. However, in the early post-trans-
plant period following myeloablative conditioning there is a lack of
tools for early detection of patients at risk for subsequent graft fail-
ure. For this purpose, we retrospectively evaluated all patients who
after myeloablative conditioning received peripheral blood cells
(PBSC) at our centre during 1995 to 2007 (n5 219). The indications
for transplantation were: AML (43%), ALL (23%), CML (17%),
myelodysplastic syndrome (6%), lymphoma (5%), metabolic disor-
ders (4%), and multiple myeloma (2%). Graft failure was defined
as absolute neutrophil count (ANC)\0.5  109/L or less than 5%
donor cell chimerism. Moreover, primary graft failure was set to
day 28 post-transplant, and patients who died prior to that day
were excluded from further analyses. Three patients experienced
graft failure within 100 days post-transplant (2 primary and 1 sec-
ondary graft failure), which means that the incidence of graft failure
was 1.4%. In univariate analysis, there was a tendency that the total
nucleated cell dose was associated with primary graft failure
(P5 0.06). In contrast, when analyzing risk factors for graft failure
within 100 days post-transplant the total nucleated cell dose seemed
to be unimportant (P5 0.17). Interestingly, in subanalyses the risk of
graft failure within 100 days post-transplant was markedly increased
in those patients who still had an ANC less than 0.2 109/L at day 16
post-transplant (OR5 30, P\0.01). In conclusion, we suggest that
in patients with less than 0.2  109/L in ANC 16 days post-trans-
plant one must consider interventions to avoid subsequent graft fail-
ure. For this purpose, strategies such as administration of
hematopoietic growth factors (e.g. G-CSF) or donor lymphocyte in-
fusions need further evaluation.348
IN-VIVO T-CELL DEPLETION USING THYMOGLOBULIN (THYMO) AL-
LOWS SUCCESSFUL ALLOGENEIC STEM CELL TRANSPLANTATION
(ALLO-SCT) FROM MISMATCHED, UNRELATED DONORS (MM-URD): PO-
TENTIAL INFLUENCE OF GRAFT SOURCE ON OUTCOME
Slack, J.L.1, Leis, J.F.1, Reeder, C.B.1, Mikhael, J.R.1, Tiedemann, R.E.1,
Stewart, A.K.1, Betcher, J.A.1, Higgins, M.S.1, Peterson, M.E.1, Gillette-
Kent, G.1, Tromp, L.R.1, Salzburg, D.B.2, Dial, K.L.2, Hospodar, K.L.2,
Jallo, C.H.2, Adams, R.H.2 1Mayo Clinic, Phoenix, AZ; 2Phoenix Child-
ren’s Hospital, Phoenix, AZ
Historically, allo-SCT using MM-URD has been associated
with poor outcomes, due primarily to high rates of GVHD. De-
creasing the rate of GVHD, without increasing relapse, should
lead to better outcomes and wider use of this life-saving proce-
dure. Between 6/1/05 and 9/30/09, 88 patients (pts) received a first
allo-SCT from an unrelated adult volunteer donor at Mayo Clinic
Arizona/Phoenix Children’s Hospital. This report focuses on the
subset of 69 pts transplanted for malignancy who received at least
one dose of Thymo (dose range 2.5-10 mg/kg, dependent on de-
gree of HLA mismatch) as part of their GVHD prophylactic reg-
imen (19 excluded, 9 with non-malignant disease, 10 who did not
receive Thymo due to MD preference). Forty-two pts were HLA-
identical (10/10) with their unrelated donor by high resolution
typing, while 27 were mismatched at one or more loci as follows:
1 allele mismatch (7); 1 antigen (Ag) mismatch (11); 2 allele mis-
match (2); 1 Ag and 1 allele mismatch (5); and 2 Ag mismatch (2).
The median age was 37 (0.5-75). Conditioning was ablative in 48,
reduced intensity in 21; graft source was PBSC in 47, marrow in
22. In addition to Thymo, all pts received a calcineurin inhibitor
(or sirolimus) plus methotrexate or MMF for GVHD prophylaxis.
The outcomes are shown in the Table. The estimated 2-yr overall
survival (OS) did not differ between the matched (61.1%) and mis-
matched pts (60.5%). The rates of aGVHD grades II-IV (48.6%
matched vs. 39.9% mismatched) and relapse (28.6% matched vs.
17.5% mismatched) also were not significantly different. Pts who
received mismatched marrow grafts had relatively poor outcomes
(2 yr OS 21.9%) due to increased relapse and higher than expected
NRM, which did not appear to be explained by higher disease risk.
By design, these pts received relatively high doses of Thymo (7.5-
10 mg/kg), and such high doses may have led to excessive T-cell
depletion of marrow grafts, abrogating the graft vs. malignancyeffect and leading to increased infectious mortality. In contrast,
pts receiving mismatched PBSC grafts (who received similar doses
of Thymo), had good outcomes (2 yr OS 91.5%) and low relapse
rates (2 yr rel 0%). We conclude that 1) using PBSC as graft
source and in vivo T-cell depletion, mismatched unrelated SCT
can be safely performed with excellent outcomes in adult and pe-
diatric pts with hematologic malignancy; and 2) modification of
the Thymo dose will be necessary to achieve similar success using
marrow grafts.
Outcomes by Match Grade and Graft Type
2 Yr 2 Yr aGVHD aGVHD
Match Grade Graft N OS Rel II-IV III-IVMatched Either 42 61.1% 28.6% 48.6% 8.3%
Matched PBSC 30 57.3% 30.4% 46.2% 8.1%
Matched Marrow 12 68.2% 25.4% 53.9% 8.8%Mismatched Either 27 60.5% 17.5% 39.9% 14.6%
Mismatched PBSC 17 91.5% 0.0% 41.8% 16.3%
Mismatched Marrow 10 21.9% 50.5% 37.1% 12.2%349
PERIPHERAL BLOOD CHIMERISM CAN REPLACE MARROW CHIMERISM
ANALYSES FOLLOWING ADULT ALLOGENEIC STEM CELL TRANSPLANT
Rauwerdink, C.A.1, Tsongalis, G.T.2, Hill, J.M.1, Meehan, K.R.1 1Dart-
mouth Hitchcock Medical Center, Dartmouth Medical School, and the
Norris Cotton Cancer Center, Lebanon, NH; 2DartmouthHitchcockMed-
ical Center, Dartmouth Medical School, and the Norris Cotton Cancer
Center, Lebanon, NH
Chimerism defines the amount of donor versus recipient hema-
topoiesis following allogeneic stem cell transplant (SCT). PCR-
based analyses of short tandem repeats (STRs) are commonly
used and are accurate and applicable to allogeneic transplant recip-
ients. These analyses are performed on peripheral blood and mar-
row aspirates, but it is not known if it is necessary to analyze both.
We performed a retrospective analysis of 42 consecutive adult allo-
geneic SCT recipients at our institution with available chimerism
studies. PCR and capillary electropheresis of microsatellite loci
were performed at 30, 60, and 90 days after SCT on both unfrac-
tionated blood and unfractionated marrow aspirate. Full donor chi-
merism (FDC) was defined as 95% or greater donor chimerism.
PCR analyses of STRs for chimerism performed on unfractionated
blood did not differ from results obtained on unfractionated mar-
row aspirate at 30, 60, or 90 days post transplant (P\0.0001). Pe-
ripheral blood PCR-based chimerism analyses provide similar
information as marrow aspirate analyses. Using peripheral blood
alone saves the expense of an additional analysis on marrow aspirate
and prevents an uncomfortable procedure. These findings provide
unique results suggesting larger studies in the adult population
are needed to further delineate the role of chimerism analyses
following allogeneic SCT.350
T-CELL DEPLETED ALLOGRAFTS FROM UNRELATED DONORS CONFER A
LOW RISK OF RELAPSE ON PATIENTS WITH HEMATOLOGIC MALIGNAN-
CIES
Jakubowski, A.A.1, Small, T.2, Barker, J.N.1, Boulad, F.2, Castro-
Malaspina, H.R.1, Hsu, K.C.1, Kernan, N.2, Koehne, G.1, Perales, M.-
A.1, Prockop, S.2, Scaradavou, A.2, van den Brink, M.R.M.1,
Young, J.W.1, O’Reilly, R.J.2, Papadopoulos, E.B.1 1Medicine; 2Memo-
rial Sloan-Kettering Cancer Center, New York, NY
Introduction: Allogeneic hematopoietic stem cell transplantation
(HSCT) is a curative treatment option for an expanding spectrum
of patients (pts) with a greater variety of diseases and graft sources,
cytoreductive regimens, cellular therapies, and supportive care.
